Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.33 |
| ▸ | NPC1 | O15118 | 7/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17057328 | 1.00 | RAB9A (0.33) | RAB9ANPC1KMT2ACNR2GRM5 | |
| SCHEMBL6530407 | 0.87 | MCOLN3 (0.38) | RAB9ANPC1KMT2A | |
| SCHEMBL5035956 | 0.86 | SOST (0.35) | CHRNA7 | |
| SCHEMBL29925123 | 0.83 | — | — | |
| SCHEMBL18312023 | 0.82 | RAB9A (0.33) | RAB9ANPC1KMT2ACNR2CHRNB2 | |
| SCHEMBL25010722 | 0.80 | CHRNB2 (0.39) | RAB9ANPC1KMT2ACNR2GRM5 | |
| SCHEMBL17037033 | 0.80 | CHRNB2 (0.39) | RAB9ANPC1KMT2ACNR2GRM5 | |
| SCHEMBL29850875 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL25355436 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL26694786 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | claimed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | claimed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | claimed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-7019001-B2 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | disclosed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | RAB9A 2919/4885NPC1 435/4885KMT2A 2874/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | RAB9A 2919/4885NPC1 435/4885KMT2A 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.